The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Key updates on transplant for multiple myeloma at ASH 2020
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of key updates in transplantation for newly diagnosed multiple myeloma as presented at ASH 2020. In particular, Dr Richardson highlights updates from the Phase II FORTE trial (NCT02203643) evaluating carfilzomib (K) plus lenalidomide-dexamethasone (KRd) induction-autologous stem cell transplantation (ASCT) with KRd consolidation, compared to K plus cyclophosphamide-dexamethasone (KCd)-induction-ASCT with KCd consolidation. He also discusses the Phase III EMN02/HO95 trial (NCT01208766) comparing bortezomib-melphalan-prednisone (VMP) versus high-dose melphalan plus single or double ASCT after induction with VMP. Finally, Dr Richardson talks about the long-term follow-up on the IFM 2009 trial (NCT03679351) comparing early versus late ASCT. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
